Campylobacter pyloridis, gastritis, and peptic ulceration.
- 1 April 1986
- journal article
- review article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 39 (4) , 353-365
- https://doi.org/10.1136/jcp.39.4.353
Abstract
Campylobacter pyloridis is a spiral bacterium which was seen by histopathologists several years before it was cultured in 1982 in Perth, Western Australia. It has unique cellular fatty acids, predominantly tetradecanoic acid and cis-11, 12 methylene octadecanoic acid. It also has a unique ultrastructure which is different from that of other campylobacters. C pyloridis possesses a powerful urease enzyme and produces large amounts of extracellular catalase. Both these features may be important virulence factors, allowing it to occupy a protected niche in the stomach below the mucus layer but above the gastric mucosa. Specific lesions are found in the gastric mucosa, and ultrastructural studies show the presence of adherence pedestals identical with those found with enteropathogenic Escherichia coli of the intestine. Histological examination of gastric biopsy tissue has shown that C pyloridis is strongly associated with active chronic gastritis, when polymorphonuclear leucocytes are present, and is not found on normal mucosa except when a biopsy specimen from elsewhere in the stomach shows active chronic gastritis. When patients with symptoms caused by gastritis are identified dual antibacterial treatment, combining the action of bismuth in the stomach with a systemic antibiotic, can eradicate C pyloridis, with remission of symptoms and restoration of normal epithelial morphology. Most peptic ulcers relapse after modern acid reducing treatment, and antibacterial treatment may be beneficial in preventing relapse.Keywords
This publication has 65 references indexed in Scilit:
- Will antibacterial chemotherapy be efficacious for gastritis and peptic ulcer?Journal of Antimicrobial Chemotherapy, 1986
- CAMPYLOBACTER PYLORIDIS IS UNIQUE: GCLO-2 IS AN ORDINARY CAMPYLOBACTERThe Lancet, 1985
- THE CHOICE OF ULCER HEALING AGENT INFLUENCES DUODENAL ULCER RELAPSE RATE AND LONG‐TERM CLINICAL OUTCOMEAustralian and New Zealand Journal of Medicine, 1985
- Anorectal incontinence and rectal prolapse: differential assessment of the innervation to puborectalis and external anal sphincter muscles.Gut, 1985
- Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers.BMJ, 1985
- MICROBES, PEPTIC ULCER, AND RELAPSE RATES WITH DIFFERENT DRUGSThe Lancet, 1984
- POSITRON EMISSION TOMOGRAPHY FOR IN-VIVO MEASUREMENT OF REGIONAL BLOOD FLOW, OXYGEN UTILISATION, AND BLOOD VOLUME IN PATIENTS WITH BREAST CARCINOMAThe Lancet, 1984
- Differentiation of Vibrionaceae Species by Their Cellular Fatty Acid CompositionInternational Journal of Systematic and Evolutionary Microbiology, 1983
- ELECTRON MICROSCOPY OF CAMPYLOBACTER JEJUNIJournal of Medical Microbiology, 1979
- Ultrastructure of cell migration throught the gastric epithelium and its relationship to bacteria.Journal of Clinical Pathology, 1975